00:20:30 Ross Center: Email trainings@rosscenter.com for assistance. 00:22:27 Jay Eubanks: Jay Eubanks, LCSW-C, Psychological Solutions, jay2day@verizon.net 00:27:04 Alicia Clark: At some point could you please explain if Ketamine is considered in the same class if these psychedelics? Thanks 00:28:51 Jay Eubanks: Jay Eubanks, LCSW-C, Psychological Solutions, jay2day@verizon.net 00:29:41 Leigh Stewart: will we receive a copy of this recording? 00:31:36 Stacy Coyle: Hi Leigh, 00:31:57 Jay Eubanks: I'm checking to make sure I'm correctly logged in as it was difficult to get into zoom. Jay Eubanks 00:32:00 Stacy Coyle: yes you can receive a copy of the recording. Email us at trainings@rosscenter.com to request and we'll get it to you when the recording is set. Thanks! 00:32:39 Leigh Stewart: thanks so much 00:33:08 Stacy Coyle: Thank you Jay! Your attendance is noted. Thanks for letting us know! 00:33:27 Stacy Coyle: our pleasure! 00:47:24 Alicia Clark: And is Ketamine the same as MDMA? 00:48:59 Alicia Clark: I had a treatment resistant depressed patient try Ketamine and it worsened her symptoms dramatically. She almost completed suicide. 00:51:35 Alicia Clark: At some point will you speak a bit about psychedelic therapy with anxiety? Are there contraindications? 00:51:49 Alicia Clark: Thanks 01:06:23 Alicia Clark: In the Imperial study, the higher relapse rate meant more people relapsed after psilocybin than after SSRIs? Meaning psilocybin is not as durable?? 01:06:30 Jay Eubanks: the audio is very choppy? anything I might do to improve it? 01:07:19 Gabriel Kajeckas: I am very interested in varying effectiveness of Ketamine treatments. Is the data in this presentation transferable, at least in part, to Ketamine treatment? 01:07:54 Stacy Coyle: HI Jay, sorry to hear about that. I'm not hearing it choppy on my end. I wonder if its the connection on your end? Can you email trainings@rosscenter.com and they can help you get reconnected if you need to log off and log back on to see if that will help. 01:10:13 Jay Eubanks: Great, I'll try that 01:20:10 Alicia Clark: I confused remission with relapse, please disregard above question. Thanks 01:22:50 Jay Eubanks: Jay Eubanks, LCSWC, Psychological Solutions, jay2day@verizon.net, able to log back on after convoluted process, audio now is good 01:23:41 Ross Center: Glad everything worked out! 01:37:35 Alicia Clark: Got it. Thanks! 01:40:42 Stacy Coyle: Hi there, I see your hand is up. Did you have a question or need assistance with something? 01:46:12 Gabriel Kajeckas: I asked a question on the chat and in q & a. Thanks. 01:46:36 Stacy Coyle: Ok great! 01:56:52 Ross Center: 10 minute break. The session will resume at 10:50am. 02:26:14 Chandni Bhatia: Interesting. Sounds similar to using Somatic Experiencing therapeutic practices 02:33:22 Chandni Bhatia: MOre Curious 02:33:31 Chandni Bhatia: *more just curious about their history :) 02:37:46 Stacy Coyle: This sounds very similar to the experience in DBT therapy 02:38:10 Alicia Clark: How do you protect a traumatized person from being more traumatized by facing their imagination-unconscious? 02:55:34 Alicia Clark: Can you speak to THC and the effects (potentially positive vs negative) of Cannabis to treat anxiety, depression? 02:55:37 Chandni Bhatia: appreciate the highlight on the racial differences - why do researches hypothesize the limited racial inclusivity? any plans on addressing the disparity? 02:58:52 Deborah O'Brien: Yes sounds like he is recommending racial diversity in the future. Although with the Black population maybe resistance due to fears and history of problematic "studies" done with that population. Don't know the stats on treatment resistant depression in this population. 02:59:24 Deborah O'Brien: The studies are usually volunteering. 03:00:18 Chandni Bhatia: I expect as normalization of psychedelics happens we may see more diversity in participant population 03:01:32 Annika Grangaard: Do you have a recommendations for how to respond to clients who are taking SSRIs or other antidepressants and engaging in recreational psychedelic use? Are there any additional risks that you haven’t discussed that we, as providers, should be aware of? 03:14:07 Katherine Hughes: I’m still curious about the Spotify playlist 03:14:53 Chandni Bhatia: Dr. Nayak - this presentation had some important foundational information about psychedelics as well as needs for more research (the racial disparities and access to care stands out)! As a therapist, providing solid psychoeducation to my clients is a big part of treatment. Thank you for presenting and conducting research in this area. Any chance you would be open to talking more over tea? - Chandni (703-927-6713)